Assessment of Resistance Mechanisms and Clinical Implications in Patients With<i>EGFR</i>T790M–Positive Lung Cancer and Acquired Resistance to OsimertinibGeoffrey R. Oxnard, Pasi A. Jänne, David J. Kwiatkowski et al.|JAMA Oncology|2018Cited by 689
<i>MET</i> Exon 14 Mutations in Non–Small-Cell Lung Cancer Are Associated With Advanced Age and Stage-Dependent <i>MET</i> Genomic Amplification and c-Met OverexpressionMark M. Awad, Lynette M. Sholl, Geoffrey R. Oxnard et al.|Journal of Clinical Oncology|2016Cited by 687
Prospective Validation of Rapid Plasma Genotyping for the Detection of<i>EGFR</i>and<i>KRAS</i>Mutations in Advanced Lung CancerAdrian G. Sacher, Geoffrey R. Oxnard, Cloud P. Paweletz et al.|JAMA Oncology|2016Cited by 567
Natural History and Molecular Characteristics of Lung Cancers Harboring EGFR Exon 20 InsertionsGeoffrey R. Oxnard, Pasi A. Jänne, Peter Lo et al.|Journal of Thoracic Oncology|2013Cited by 358
Expression of PD-1 and Its Ligands, PD-L1 and PD-L2, in Smokers and Never Smokers with KRAS-Mutant Lung CancerAntonio Calles, Pasi A. Jänne, Xiaoyun Liao et al.|Journal of Thoracic Oncology|2015Cited by 290